Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Cellectar Biosciences, Inc.
Baylor College of Medicine
St. Jude Children's Research Hospital
ITM Solucin GmbH
University of Arizona
St. Jude Children's Research Hospital
Lantern Pharma Inc.
ImmunityBio, Inc.
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Juno Therapeutics, a Subsidiary of Celgene
Genzada Pharmaceuticals USA, Inc.
BTG International Inc.
Providence Health & Services
The University of Texas Health Science Center, Houston
Case Comprehensive Cancer Center
Baylor College of Medicine
Celgene
Memorial Sloan Kettering Cancer Center
Tocagen Inc.
Acrotech Biopharma Inc.
National Institutes of Health Clinical Center (CC)
University of Maryland, Baltimore
National Institutes of Health Clinical Center (CC)
Daiichi Sankyo
M.D. Anderson Cancer Center
Providence Health & Services
Masonic Cancer Center, University of Minnesota
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Dana-Farber Cancer Institute
University of Alabama at Birmingham
SillaJen, Inc.
The Cleveland Clinic
Valerio Therapeutics
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Hospital of Philadelphia
Cellerant Therapeutics
Children's Oncology Group
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Children's Oncology Group
Washington University School of Medicine
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
Boston Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis